Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress of the integrative and molecular targeted therapies on pancreatic cancer

( views:211, downloads:22 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 21

DOI:: 10.3969/j.issn.1009-3079.2006.21.001

Key Word:: 胰腺癌;中西医综合治疗;分子靶向治疗;基因治疗

Abstract：胰腺癌预后不良,死亡率高居消化道癌症第5位.现代医学对胰腺癌的病因尚未完全清楚,但随着肿瘤发生、发展分子机制的逐步了解,癌细胞与正常细胞的区别将会更加明确,一些癌细胞特有的分子靶点将成为胰腺癌诊疗的有用工具.基因检测和蛋白质检测,以及手术治疗、放射治疗和化学治疗为本病常用的诊疗方法.另一方面,中医辨证施治、标本兼治、阴阳平衡等方法和理论,如能恰当地融合到西医对胰腺癌的综合诊疗中,定将提高治愈率,并能改善患者的生存质量.此外,分子靶向治疗如免疫治疗、核糖核酸干扰等在近年来蓬勃兴起,尽管其技术仍需改善,疗效有待提高,但已给恶性肿瘤的诊疗带来了希望.本文对胰腺癌作出较详尽的介绍,并阐述目前胰腺癌诊疗的最新进展.

Reference

[1]王丽,李辉.胰腺癌遗传流行病学研究进展[J].2006,(2).
[2]Hai-Tao Guan,Xing-huan Xue,Zhi-Jun Dai,etc.Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity[J].2006,(18).
[3]Seok Jeong,Don Haeng Lee,Jung Il Lee,etc.Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma[J].2005,(43).
[4]何杨,杨波,RUAN Chang-Geng.树突细胞负载K-ras突变多肽诱导抗胰腺癌免疫反应[J].2005,(5).
[5]管海涛,薛兴欢,王西京,等.靶向survivin的siRNA诱导胰腺癌细胞凋亡的实验研究[J].2006,(2).
[6]Xie K,Wei D,Huang S.Transcriptional anti-angiogenesis therapy of human pancreatic cancer.[J].2006,17(3).
[7]Angelini C,Bovo G,Muselli P,etc.Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.[J].2006,53(67).
[8]Norihiro, Sato,Noriyoshi, Fukushima,Hiroyuki, Matsubayashi,etc.Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.[J].2006,107(2).
[9]Kristiansen TZ,Iwahori A,Gronborg M,etc.Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.[J].2006,5(1).
[10]Schmied BM,Chauhan SC,Sikela JM,etc.The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis.[J].2006,25(23).
[11]Jiao L,Evans DB,Crane CH,etc.Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.[J].2006,24(11).
[12].Expression of P53, P16 and Cox-2 in Pancreatic Cancer with Tissue Microarray[J].2006,(1).
[13]Mullerad M,Chan MK,Yu Z,etc.5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.[J].2005,9(8).
[14]Larsson SC,Hakansson N,Naslund I,etc.Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study.[J].2006,15(2).
[15]Gourdas, Choudhuri,Divya, Singh.Molecular mechanisms of pancreatic cancer.[J].1900,26(3).
[16]Jain A,Kono E,Berberat PO,etc.Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.[J].2005,31(2).
[17]Bhardwaj A,Ellison EC,Bloomston M,etc.Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique.[J].2006,23(1).
[18]Kenneth H. Yu,Ian A. Blair,Anil K. Rustgi.Characterization of Proteins in Human Pancreatic Cancer Serum Using Differential Gel Electrophoresis and Tandem Mass Spectrometry[J].2005,4(5).
[19]Giroux V..p8 Is a New Target of Gemcitabine in Pancreatic Cancer Cells[J].2006.
[20]Moore MJ,Tang PA,Tsao MS.A review of erlotinib and its clinical use.[J].2006,7(2).
[21]Chiz S,Della Manna D,Kaliberov SA,etc.Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.[J].2006,13(2).
[22]Yin S,Goodrich DW.Combination gene therapy with p53 and Thoc1/p84 is more effective than either single agent in an animal model of human pancreatic adenocarcinoma.[J].2006,28(3).
[23]Lemoine NR,Bhattacharyya M.Gene therapy developments for pancreatic cancer.[J].2006,20(2).
[24]Gorunescu F,Cazacu S,Ciurea T,etc.Power Doppler endoscopic ultrasonography for the differential diagnosis between pancreatic cancer and pseudotumoral chronic pancreatitis.[J].2006,25(3).
[25]Wolff RA,Ho L,Charnsangavej C,etc.Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.[J].2006,24(7).
[26]Yekebas EF,Schneider C,Strate T,etc.Surgery for advanced and metastatic pancreatic cancer--current state and perspectives.[J].2006,26(1B).
[27]Lieberman J,Dykxhoorn DM.Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.[J].2006,8(0).
[28]MacKenzie MJ.Molecular therapy in pancreatic adenocarcinoma.[J].2004,5(9).
[29]Plate JM,Harris JE.Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer.[J].2005,94(6).
[30]Fogar P,Greco E,Pedrazzoli S,etc.Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides.[J].2004,343(1).
[31]P, Malfertheiner,K, Schütte.Smoking--a trigger for chronic inflammation and cancer development in the pancreas.[J].2006,101(1).
[32]Wagner TD,Yang GY,Fuss M,etc.Multimodality approaches for pancreatic cancer.[J].2005,55(6).
[33]Goodlett DR,Aebersold R,Yi EC,etc.Quantitative proteomic profiling of pancreatic cancer juice[J].2006,6(13).
[34]Nordling S,Haglund C,Juuti A,etc.Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.[J].2006,59(4).
[35]Mohler M,Jakobs R,Eickhoff A,etc.A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.[J].2006,94(11).
[36]Yagihashi A,Tsuji N,Kobayashi D,etc.Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells.[J].2005,25(6B).
[37]Pisani P,Ferlay J,Parkin DM,etc.Global cancer statistics, 2002.[J].2005,55(2).
[38]Passoni P,Balzano G,Brandes AA,etc.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.[J].2006,94(6).
[39]Jian Z,Lv X,Chen Z,etc.XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics.[J].2006,32(3).
[40]Donadelli M,Costanzo C,Palmieri M,etc.Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.[J].2006,448(6).
[41]Comstock GW,Gallicchio L,Genkinger JM,etc.Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer.[J].2006,42(3).